Guzman Raphael, Lee Marco, Achrol Achal, Bell-Stephens Teresa, Kelly Michael, Do Huy M, Marks Michael P, Steinberg Gary K
Department of Neurosurgery, Stanford University School of Medicine, Stanford, California 94305-5487, USA.
J Neurosurg. 2009 Nov;111(5):927-35. doi: 10.3171/2009.4.JNS081649.
Moyamoya disease (MMD) is a rare cerebrovascular disease mainly described in the Asian literature. To address a lack of data on clinical characteristics and long-term outcomes in the treatment of MMD in North America, the authors analyzed their experience at Stanford University Medical Center. They report on a consecutive series of patients treated for MMD and detail their demographics, clinical characteristics, and long-term surgical outcomes.
Data obtained in consecutive series of 329 patients with MMD treated microsurgically by the senior author (G.K.S.) between 1991 and 2008 were analyzed. Demographic, clinical, and surgical data were prospectively gathered and neurological outcomes assessed in postoperative follow-up using the modified Rankin Scale. Association of demographic, clinical, and surgical data with postoperative outcome was assessed by chi-square, uni- and multivariate logistic regression, and Kaplan-Meier survival analyses.
The authors treated a total of 233 adult patients undergoing 389 procedures (mean age 39.5 years) and 96 pediatric patients undergoing 168 procedures (mean age 10.1 years). Direct revascularization technique was used in 95.1% of adults and 76.2% of pediatric patients. In 264 patients undergoing 450 procedures (mean follow-up 4.9 years), the surgical morbidity rate was 3.5% and the mortality rate was 0.7% per treated hemisphere. The cumulative 5-year risk of perioperative or subsequent stroke or death was 5.5%. Of the 171 patients presenting with a transient ischemic attack, 91.8% were free of transient ischemic attacks at 1 year or later. Overall, there was a significant improvement in quality of life in the cohort as measured using the modified Rankin Scale (p < 0.0001).
Revascularization surgery in patients with MMD carries a low risk, is effective at preventing future ischemic events, and improves quality of life. Patients in whom symptomatic MMD is diagnosed should be offered revascularization surgery.
烟雾病(MMD)是一种罕见的脑血管疾病,主要在亚洲文献中有描述。为了解决北美地区烟雾病治疗方面临床特征和长期预后数据的缺乏,作者分析了他们在斯坦福大学医学中心的经验。他们报告了一系列连续治疗的烟雾病患者,并详细阐述了患者的人口统计学特征、临床特征和长期手术结果。
分析了1991年至2008年间由资深作者(G.K.S.)显微手术治疗的329例烟雾病连续系列患者的数据。前瞻性收集人口统计学、临床和手术数据,并在术后随访中使用改良Rankin量表评估神经学结果。通过卡方检验、单因素和多因素逻辑回归以及Kaplan-Meier生存分析评估人口统计学、临床和手术数据与术后结果的相关性。
作者共治疗了233例成年患者,进行了389次手术(平均年龄39.5岁)和96例儿科患者,进行了168次手术(平均年龄10.1岁)。95.1%的成年患者和76.2%的儿科患者采用了直接血管重建技术。在264例接受450次手术的患者中(平均随访4.9年),每个治疗半球的手术发病率为3.5%,死亡率为0.7%。围手术期或随后中风或死亡的累积5年风险为5.5%。在171例短暂性脑缺血发作患者中,91.8%在1年或更晚时无短暂性脑缺血发作。总体而言,使用改良Rankin量表测量,该队列的生活质量有显著改善(p < 0.0001)。
烟雾病患者的血管重建手术风险较低,能有效预防未来的缺血性事件,并改善生活质量。被诊断为有症状烟雾病的患者应接受血管重建手术。